A pH-Responsive Nanoplatform Inducing Synergistic Cuproptosis and Pyroptosis Reprograms the Immunosuppressive Tumor Microenvironment for Enhanced Immunotherapy
Source abstract
Abstract
In this study, a pH-responsive Cu-doped zeolitic imidazolate framework-8 nanoplatform was coloaded with paclitaxel and doxorubicin for synergistic tumor therapy. Hyaluronic acid modification on the outer surface of the nanomaterials enhances tumor targeting via CD44 receptor-mediated endocytosis. ZIF-8, derived from metal–organic frameworks, is an excellent nanocapsulator capable of specifically responding to the acidic tumor microenvironment. Upon reaching the tumor site, it rapidly degrades, releasing copper ions and chemotherapeutic drugs to exert antitumor effects. Copper ions consume endogenous hydrogen peroxide and glutathione through Fenton-like reactions, thereby generating cytotoxic reactive oxygen species, enhancing chemodynamic therapy efficiency, and inducing cuproptosis. The released PTX and DOX not only exert chemotherapeutic effects but also induce pyroptosis by activating the classical pathway mediated by caspase-3 and Gasdermin E. Due to excessive activation of the Wnt/β-catenin signaling pathway, PTX faces drug resistance in the treatment of triple-negative breast cancer, whereas DOX can inhibit this pathway by promoting β-catenin degradation. These therapies act synergistically to trigger immunogenic cell death, release damage-associated molecular patterns, promote dendritic cell maturation, activate T cells, and effectively reshape the immunosuppressive tumor microenvironment. This multimodal nanoplatform demonstrates remarkable potential as an antitumor treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Inflammasome and immune disorders · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Medicine
Linyi University
School of Chemistry and Chemical Engineering
Qilu Normal University
Key Laboratory of Advanced Biomaterials and Nanomedicine in Universities of Shandong
Funding
Linyi University
References (62)
Show source-provided references
1. 10.3322/caac.2187110.3322/caac.21871 ↗
2. 10.1038/s41591-025-03502-310.1038/s41591-025-03502-3 ↗
3. 10.1038/s41597-023-02253-510.1038/s41597-023-02253-5 ↗
4. 10.1186/s40364-024-00714-610.1186/s40364-024-00714-6 ↗
5. 10.3390/cancers812010610.3390/cancers8120106 ↗
6. 10.1016/j.bioactmat.2023.01.01410.1016/j.bioactmat.2023.01.014 ↗
7. 10.1016/j.semcancer.2019.07.02110.1016/j.semcancer.2019.07.021 ↗
8. 10.3389/fimmu.2024.151342110.3389/fimmu.2024.1513421 ↗
9. 10.1186/s13046-025-03394-810.1186/s13046-025-03394-8 ↗
10. 10.3390/cancers1416393510.3390/cancers14163935 ↗
11. 10.1038/s41598-025-03542-210.1038/s41598-025-03542-2 ↗
12. 10.1016/j.bioactmat.2020.08.03610.1016/j.bioactmat.2020.08.036 ↗
13. 10.1039/c2dt30357d10.1039/c2dt30357d ↗
14. 10.1016/j.ijbiomac.2025.14248610.1016/j.ijbiomac.2025.142486 ↗
15. 10.1016/j.colsurfb.2025.11486010.1016/j.colsurfb.2025.114860 ↗
16. 10.3390/polym1416341010.3390/polym14163410 ↗
17. 10.1016/j.jare.2024.03.00610.1016/j.jare.2024.03.006 ↗
18. 10.1007/s00262-024-03752-z10.1007/s00262-024-03752-z ↗
19. 10.1002/adhm.20220213510.1002/adhm.202202135 ↗
20. 10.1080/21655979.2021.201897310.1080/21655979.2021.2018973 ↗
21. 10.3390/cells808089210.3390/cells8080892 ↗
22. 10.1186/s12645-025-00316-310.1186/s12645-025-00316-3 ↗
23. 10.3390/cells1204065910.3390/cells12040659 ↗
24. 10.1007/s13346-024-01654-210.1007/s13346-024-01654-2 ↗
25. 10.1111/jcmm.1657410.1111/jcmm.16574 ↗
26. 10.1186/s12951-022-01278-z10.1186/s12951-022-01278-z ↗
27. 10.3390/pharmaceutics1509233710.3390/pharmaceutics15092337 ↗
28. 10.1002/anie.20180566410.1002/anie.201805664 ↗
29. 10.1039/C7CS00471K10.1039/C7CS00471K ↗
30. 10.1002/adma.20190177810.1002/adma.201901778 ↗
31. 10.1021/jacs.9b0345710.1021/jacs.9b03457 ↗
32. 10.1021/acsabm.0c0009810.1021/acsabm.0c00098 ↗
33. 10.1126/science.abf052910.1126/science.abf0529 ↗
34. 10.1002/mco2.72410.1002/mco2.724 ↗
35. 10.1039/D5CS00083A10.1039/D5CS00083A ↗
36. 10.1007/s11596-024-2832-z10.1007/s11596-024-2832-z ↗
37. 10.1016/j.jconrel.2024.01.05710.1016/j.jconrel.2024.01.057 ↗
38. 10.1002/adhm.20220123310.1002/adhm.202201233 ↗
39. 10.1038/s41419-023-06382-y10.1038/s41419-023-06382-y ↗
40. 10.1038/s41420-020-00349-010.1038/s41420-020-00349-0 ↗
41. 10.3892/ol.2023.1396210.3892/ol.2023.13962 ↗
42. 10.1016/j.it.2022.04.00510.1016/j.it.2022.04.005 ↗
43. 10.1186/s12964-023-01234-w10.1186/s12964-023-01234-w ↗
44. 10.1038/s41573-024-00920-910.1038/s41573-024-00920-9 ↗
45. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
46. 10.1038/s41392-022-01046-310.1038/s41392-022-01046-3 ↗
47. 10.1002/cac2.1253910.1002/cac2.12539 ↗
48. 10.1021/acsomega.3c0006810.1021/acsomega.3c00068 ↗
49. 10.3390/cancers1201016210.3390/cancers12010162 ↗
50. 10.1039/D1RA01574E10.1039/D1RA01574E ↗
51. 10.3389/fphar.2024.140159410.3389/fphar.2024.1401594 ↗
52. 10.1016/j.jcou.2021.10152310.1016/j.jcou.2021.101523 ↗
53. 10.1039/D2RA02775E10.1039/D2RA02775E ↗
54. 10.1021/acs.est.0c0528710.1021/acs.est.0c05287 ↗
55. 10.1021/acs.analchem.4c0366510.1021/acs.analchem.4c03665 ↗
56. 10.1038/s12276-020-0384-210.1038/s12276-020-0384-2 ↗
57. 10.1016/j.impact.2024.10052110.1016/j.impact.2024.100521 ↗
58. 10.1016/j.carbpol.2020.11598110.1016/j.carbpol.2020.115981 ↗
59. 10.1002/smll.20230114810.1002/smll.202301148 ↗
60. 10.1002/advs.20240104710.1002/advs.202401047 ↗
61. 10.1016/j.biomaterials.2023.12233310.1016/j.biomaterials.2023.122333 ↗
62. 10.1002/anie.20221530710.1002/anie.202215307 ↗